09/19/23 8:00 AMNasdaq : BIAF, BIAFW acquisitionlow floatbioAffinity Technologies Acquires Laboratory Assets of Precision Pathology ServicesbioAffinity Technologies, Inc., a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists and certified under...RHEA-AIvery positive
09/07/23 8:00 AMNasdaq : BIAF, BIAFW conferenceslow floatbioAffinity Technologies to Participate in the H.C. Wainwright Global Investment ConferencebioAffinity Technologies, Inc., a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, today announced that Maria Zannes, President and CEO, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25 th Annual Global Investment Conference being held September...RHEA-AIneutral
08/14/23 5:03 PMNasdaq : BIAF, BIAFW earningslow floatbioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business UpdateCPT codes provide a uniform system to identify medical services and procedures and seek reimbursement from private payers and public health insurance programs, including Medicare and Medicaid. The Department of Defense purchased CyPath Lung ® tests for use in an observational study on active military personnel at high risk for developing lung cancer...RHEA-AIneutral
07/12/23 8:00 AMNasdaq : BIAF, BIAFW low floatAMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung CancerbioAffinity Technologies, Inc., a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, today announced that the American Medical Association has released a Current Procedural Terminology code specifically for use with CyPath ® Lung, a noninvasive test for early-stage lung cancer. Created and maintained by...RHEA-AIneutral
06/15/23 8:00 AMNasdaq : BIAF, BIAFW low floatbioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics SymposiumbioAffinity Technologies, Inc., a biotechnology company addressing the need for early-stage cancer detection and broad-spectrum cancer therapeutics, will present the poster“ Vitamin B12 deprivation does not phenocopy selective cytotoxicity of CD320 and LRP2 silencing” at the University of Massachusetts T.H. Chan Medical School’ s fifth annual RNA...RHEA-AInegative
05/22/23 8:00 AMNasdaq : BIAF, BIAFW low floatbioAffinity Technologies Presents Research Findings at CYTO 2023bioAffinity Technologies, Inc., a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today will present the poster“ Development of porphyrin-stained polystyrene compensation beads for use on an automated analysis platform” at CYTO 2023, the annual Congress for the International...RHEA-AIneutral
05/15/23 8:00 AMNasdaq : BIAF, BIAFW earningslow floatbioAffinity Technologies Reports First Quarter 2023 Financial ResultsDougherty most recently served as CFO of Amazon’ s Alexa commercial domains, where he was responsible for financial strategy over Alexa’ s multibillion-dollar investments in AI-generated customer experiences. Engaged Havas Health& You and Trinity Life Sciences to create the branding and marketing strategy for CyPath ® Lung. Continued with the initial...RHEA-AIneutral
05/01/23 8:00 AMNasdaq : BIAF, BIAFW low floatbioAffinity Technologies Names Michael Dougherty as Chief Financial OfficerDougherty is an experienced C-level executive with more than 20 years in financial management and business strategy. Dougherty will report directly to bioAffinity Technologies President and Chief Executive Officer Maria Zannes. Dougherty was Chief Financial Officer of Alexa Business Domains, Amazon’ s Alexa AI and Voice division, where he was...RHEA-AIneutral
04/25/23 8:00 AMNasdaq : BIAF, BIAFW low floatbioAffinity Technologies Presents at Cleveland Clinic Lung Cancer SymposiumbioAffinity Technologies, Inc., a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, will present at the Cleveland Clinic’ s invitation-only Advances in Early Lung Cancer Detection annual symposium in Cleveland, Ohio, on April 27, 2023. bioAffinity Technologies, Inc. addresses the need for...RHEA-AIneutral
04/05/23 8:00 AMNasdaq : BIAF, BIAFW, NDAQ low floatbioAffinity Technologies to Ring Nasdaq Closing Bell TodaybioAffinity Technologies, Inc., a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, will ring the Nasdaq Stock Market closing bell this afternoon to commemorate the Company’ s 2022 initial public offering. The Nasdaq Stock Market closing bell ceremony will run from approximately 3:45 to...RHEA-AIneutral
